Poor
Not Aligned
Patient Risk:
Medium
Summary
Several safety-related claims (drug interactions, risk-factor susceptibility, and expanded hepatic sequelae) are not supported by the provided label excerpts, and some statements appear overextended beyond what is explicitly described.
Category Scores
Accurate Statements
Lipitor works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action
Lipitor blocks the enzyme HMG-CoA reductase.
12.1 Mechanism of Action
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action
Lipitor can cause an increase in liver enzymes, such as alanine transaminase (ALT) and aspartate transaminase (AST).
5.2 Liver Dysfunction; 17.2 Liver Enzymes
In severe cases, Lipitor can cause liver failure.
6.2 Postmarketing Experience (hepatic failure)
Monitoring liver function while taking Lipitor can be done through regular blood tests that measure liver enzymes and other markers of liver health.
5.2 Liver Dysfunction; 17.2 Liver Enzymes
Unsupported Statements
Lipitor (atorvastatin) is a statin medication.
Not supported by the provided label excerpts.
Lipitor lowers the risk of heart disease and stroke.
Not supported by the provided label excerpts.
Obese individuals may be more prone to liver damage from Lipitor.
Not supported by the provided label excerpts.
Warfarin can increase the risk of liver damage when taken with Lipitor.
The provided label excerpt for warfarin states no clinically significant effect on prothrombin time; it does not support an increased liver-damage risk.
Amiodarone can increase the risk of liver damage when taken with Lipitor.
No amiodarone interaction information is present in the provided label excerpts.
Contradictions
Low
AI Statement
Warfarin can increase the risk of liver damage when taken with Lipitor.
Label Reference
7.7 Warfarin (states no clinically significant effect on prothrombin time when administered with chronic warfarin).
Important Omissions
Major label safety content relevant to assessing safety completeness (e.g., contraindications/boxed warnings/pregnancy/pediatric use) is not addressed in the claims provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported or overextended hepatic-risk and interaction claims (e.g., warfarin/amiodarone liver-damage risk, obesity susceptibility, and mapping to hepatitis/cirrhosis) could misinform risk assessment relative to what is explicitly supported by the provided labeling excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the provided label excerpts, including drug–drug interaction risk assertions and specific hepatic sequelae/susceptibility statements not explicitly stated in the cited text.
Suggested Improvement
Remove or revise unsupported claims; align hepatic statements to what the label excerpts explicitly state (e.g., transaminase elevations, need for LFT monitoring, and hepatic failure as an adverse reaction) and provide label-supported citations for any drug interaction or CV risk-reduction claims.